Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer

Table 1 Baseline clinicopathological characteristics

Variables	Seroclearance (n = 72)	Non-seroclearance (n = 216)	P value
Ages [median (range)]	63.5 ± 8.9	57.0 ± 9.0	< 0.001
Sex (male:female)	59:17	171:45	0.871
Hemoglobin (mg/dL)	130.6 ± 28.0	135.3 ± 21.7	0.144
Platelet count (× 109/µL)	163.2 ± 87.5	126.7 ± 76.2	0.001
PTA (%)	90.5 ± 20.7	87.7 ± 18.5	0.282
Albumin (g/L)	40.5 ± 5.6	40.1 ± 5.9	0.675
AST (IU/L)	33.3 ± 28.6	39.9 ± 36.7	0.163
ALT (IU/L)	36.9 ± 40.7	42.4 ± 41.7	0.327
TBil (µmol/L)	21.2 ± 20.9	19.8 ± 17.5	0.567
AFP (ng/mL)
≤ 15	36	100	0.456
15-200	19	54
≥ 200	17	62
Size of tumor (cm) [median (range)]	5.4 (1-15.4)	4.35 (1-15)	0.064
Number of tumor nodules
Solitary	51	138	0.318
Multiple	21	78
Treatment
Resection	26	78	-
Ablation Tx	23	69
TACE	26	78
AJCC 8th edition
Stage I	41	123	-
Stage II	9	27
Stage III	22	66
Child-Pugh grade
A	67	171	-
B	14	42
C	1	3

PTA: Prothrombin time activity; AST: Aspartate aminotransferase (Normal range 15-40 U/L); ALT: Alanine aminotransferase (Normal range 9-50 U/L); TBil: Total billirubin (Normal range 5.1-19.0 μmol/L); AFP: Alpha fetoprotein (Normal range < 15 ng/mL); TACE: Transhepatic arterial chemotherapy and embolization.